A study presented at the American Diabetes Association Scientific Sessions found that oral fenofibrate, a lipid-lowering drug, was associated with a 27% reduction in progression of diabetic eye disease over 4 years. This drug, repurposed for the LENS trial, showed significant benefits in reducing diabetic retinopathy and maculopathy. The study involved over 1,100 adults with type 1 or type 2 diabetes and early to moderate eye disease, with participants taking fenofibrate showing lower rates of disease progression compared to those taking a placebo. The researchers suggest further trials to explore the potential benefits of fenofibrate in other eye conditions.
Source link
Fenofibrate reduces progression of diabetic eye disease
